Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

CT scans may offer a Needle-Free way to diagnose Lung-Heart condition

NCT ID NCT07667595

Knowledge-focused Sponsor: Assiut University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study will look at 60 adults with a type of high blood pressure in the lungs (pre-capillary pulmonary hypertension) to see if measurements from a CT scan match those from a standard invasive heart catheter test. If the CT scan proves reliable, it could offer a safer, less invasive way to diagnose and monitor this condition. Participants must have both tests done within 4 weeks of each other.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this could show that CT scans are reliable enough to reduce the need for invasive heart catheterization in diagnosing pulmonary hypertension.
What could go wrong
This is an observational study with only 60 participants, so results may not apply to all patients. The CT and catheter measurements must be taken within 4 weeks, which may limit accuracy.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 60 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Jun 2026

An estimate. Start dates often move.

Expected to finish

Jul 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

adults with precapillary PHTN with contraindications to CTPA

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1-Age ≥ 18 years at time of enrolment. 2-Confirmed pre-capillary pulmonary hypertension on RHC performed at Assiut University Hospital: mPAP \> 20 mmHg AND PAWP ≤ 15 mmHg AND PVR ≥ 2 Wood Units. 3-WHO PH Clinical Group 1 (PAH), Group 3 (PH due to lung disease/hypoxia), or Group 4 (CTEPH / chronic thromboembolic PH) classification assigned by the PH-MDT. 4-Both CTPA and RHC performed within a maximum interval of 4 weeks. b. Exclusion criteria: 1. WHO PH Group 2 (PH due to left heart disease) or Group 5 (PH with unclear/multifactorial mechanisms) . 2. Active malignancy. 3. Pregnancy, confirmed or suspected. 4. Contraindication to iodinated contrast agent: eGFR \< 30 mL/min/1.73m² OR documented history of severe anaphylactic contrast reaction. 5. Inability to sustain breath-hold of ≥ 8 seconds (impairs CTPA quality). 6. Initiation or dose escalation of pulmonary vasodilator therapy (endothelin receptor antagonist, PDE5 inhibitor, soluble guanylate cyclase stimulator, or prostanoid) in the interval between CTPA and RHC, or within 4 weeks prior to CTPA. 7. Patient refusal to consent or inability to provide informed consent

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CT angiography are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Cataract, posterior polar, 1 pulmonary hypertension

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CT angiography Precapillary pulmonary hypertension Pulmonary hypertension Right heart catheterisation

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Assiut University Hospital

    Asyut, Asyut Governorate, 71515, Egypt

More trials for these conditions

Other studies related to the condition(s) this trial covers.